Parkinson’s disease is often described as a single disorder, but a new analysis of donated human brain tissue suggests that its defining protein pathology can vary dramatically from one patient to another. Researchers at the Mayo Clinic found substantial differences in the amount, chemical modification, aggregation behavior and “seeding” activity of alpha-synuclein, the protein that accumulates in the brains of people with Parkinson’s disease. The findings raise the possibility that patients who receive the same clinical diagnosis may nevertheless harbor biologically distinct forms of disease—an observation that could reshape efforts to develop precision treatments and molecular tests.

The study, published in Acta Neuropathologica, examined postmortem samples from 63 people of European descent, including patients with neuropathologically confirmed Parkinson’s disease and individuals without Lewy body pathology. The Parkinson’s cases were divided according to age at disease onset and clinical duration. Early-onset disease was defined as beginning before age 60, while late-onset disease began after age 60. The late-onset group was further divided into fast-progressing cases, with disease duration of less than five years, and slow-progressing cases, with disease lasting more than 10 years. This design allowed the team to compare molecular features not only between patients and controls, but also among clinically recognizable forms of Parkinson’s disease.

Alpha-synuclein is normally associated with nerve terminals, where it is thought to help regulate synaptic vesicles—the small membrane packages that carry neurotransmitters between neurons. In Parkinson’s disease, however, the protein can misfold and assemble into fibrils and larger inclusions known as Lewy bodies and Lewy neurites. These deposits are a pathological hallmark of Parkinson’s and related synucleinopathies. Misfolded alpha-synuclein can also act as a molecular “seed”: when introduced into cells, it can recruit normally folded alpha-synuclein and convert it into new aggregates. This templating process is sometimes described as prion-like, although it does not imply that Parkinson’s disease spreads between people. Instead, it refers to the ability of a misfolded protein to propagate through connected cells and brain regions.

To isolate disease-associated protein species, the researchers dissected tissue from the cingulate gyrus, a limbic cortical region involved in motor integration, cognition and neuropsychiatric function. They separated proteins according to their solubility, focusing particularly on detergent-insoluble material, which is enriched for tightly packed aggregates. The team measured total alpha-synuclein and alpha-synuclein phosphorylated at serine 129, or pSer129. This chemical modification is strongly enriched in Lewy pathology and is widely used as a laboratory marker of abnormal alpha-synuclein. Using a bead-based immunoassay called AlphaLISA, the researchers found that pSer129-alpha-synuclein was significantly elevated across all Parkinson’s groups compared with controls. Total alpha-synuclein, by contrast, was especially high in late-onset Parkinson’s disease, exceeding levels in both early-onset cases and controls.

The researchers then tested whether the brain-derived material could trigger aggregation in living cells. They used engineered human kidney cells containing two versions of alpha-synuclein, one tagged with cyan fluorescent protein and the other with yellow fluorescent protein. When alpha-synuclein molecules come into close proximity during aggregate formation, energy can transfer between the fluorescent tags, producing a measurable FRET signal. Flow cytometry allowed the researchers to quantify this response across thousands of cells, using an integrated measure that combined the proportion of FRET-positive cells with the intensity of their signal. Every Parkinson’s sample produced more seeding activity than control material, but the most striking result was the variation among individual patients. Seeding activity differed by more than tenfold across cases, and that spread was greater than the average differences separating the predefined clinical subgroups.

The cell experiments also suggested that the signal reflected alpha-synuclein itself rather than a nonspecific toxic effect of brain extracts. When the researchers removed alpha-synuclein from selected homogenates using an antibody attached to magnetic beads, alpha-synuclein levels fell by an average of 64 percent and the integrated FRET signal declined by about 71 percent. Cell viability did not differ significantly between groups, indicating that the stronger fluorescence response was not simply caused by acute cell death or generalized cellular stress. High-content imaging provided an independent confirmation: Parkinson’s samples generated more intracellular puncta, or aggregate-like structures, than control samples. Slow-progressing late-onset cases showed a greater aggregate burden than fast-progressing cases, although much of the variation still appeared to be driven by individual biology.

The relationship between chemical modification and aggregation was particularly revealing. Across Parkinson’s cases, higher pSer129-alpha-synuclein levels correlated positively with stronger FRET seeding activity. Lewy body counts in the cingulate cortex also correlated with both pSer129 levels and the cellular seeding readout. These associations suggest that phosphorylation at serine 129 tracks with the abundance of biologically active aggregate species, but they do not prove that phosphorylation initiates disease or directly causes propagation. Alpha-synuclein can be phosphorylated in healthy neurons in response to normal neuronal activity, and some evidence indicates that serine-129 phosphorylation may occur after aggregation or even inhibit certain forms of fibril formation. In this study, therefore, pSer129 is best interpreted as a molecular correlate of pathology and aggregation dynamics rather than as a definitive trigger.

The team next used a cell-free seed amplification assay known as RT-QuIC, short for real-time quaking-induced conversion. In this technique, a minute amount of patient-derived seed is mixed with purified, normally folded human alpha-synuclein. Repeated shaking and incubation encourage any seed present to convert the soluble protein into fibrils. The reaction contains thioflavin T, a fluorescent dye whose signal rises as amyloid-like structures accumulate. The time required for fluorescence to cross a predefined threshold—the lag time—provides an indirect measure of how efficiently aggregation begins. Parkinson’s samples crossed the threshold substantially faster than controls, with a mean lag time of 26.9 hours compared with 45.1 hours. The assay produced an area under the receiver operating characteristic curve of 0.98; in this dataset, a lag time below 34.7 hours corresponded to 93 percent sensitivity and 100 percent specificity.

RT-QuIC also exposed differences in the physical stability of the amplified aggregates. After amplification, the researchers treated the products with proteinase K, an enzyme that digests exposed or loosely structured protein regions, and analyzed the remaining fragments by gel electrophoresis and silver staining. Products generated from Parkinson’s samples were more resistant to digestion than those from controls at every time point, indicating that the seed-competent assemblies had different structural properties. However, the researchers did not find a single protease-resistance pattern that cleanly separated early- from late-onset disease or fast- from slow-progressing cases. The results instead point to molecular heterogeneity between individuals. Because amplified fibrils can differ from the original brain-derived aggregates, the assay does not provide a complete structural portrait of pathology in the brain, but it offers a reproducible way to compare the biochemical behavior of disease-associated seeds.

Genetic variation may contribute to this diversity. Two of the three patients with the strongest combination of FRET seeding activity and pSer129-alpha-synuclein carried the APOE E3/E4 genotype, and the APOE4 allele was more common in the fast-progressing late-onset group than in the slow-progressing group. APOE4 is best known as a risk factor for Alzheimer’s disease, but previous research has linked it to alpha-synuclein aggregation, neurotoxicity and more aggressive synucleinopathy. The current findings are suggestive rather than conclusive: the study was not designed to establish that APOE4 causes stronger seeding, and the most extreme molecular profiles were not all explained by that genotype. Age-related cellular decline, genetic variants, mitochondrial dysfunction, protein-clearance capacity and other environmental or biological factors could all influence the shape that alpha-synuclein takes in a particular brain.

The implications extend beyond a new way of dividing Parkinson’s disease. Clinical categories such as early onset, late onset, rapid progression and slow progression remain useful, but they did not fully capture the molecular differences measured in this study. That conclusion aligns with emerging biological frameworks, including SynNeurGe and the Neuronal alpha Synuclein Disease Integrated Staging System, which seek to classify Parkinson’s disease using evidence of pathogenic alpha-synuclein, neurodegeneration, genetic risk and clinical features. A future diagnostic system might combine seed amplification, phosphorylation patterns, genetic information and imaging rather than relying on symptoms alone. Such tests could eventually help predict disease trajectory, identify patients most likely to benefit from alpha-synuclein-targeting therapies, or reveal why an intervention works in one patient but fails in another. The present study is based on a relatively small, postmortem cohort with incomplete detailed clinical information, so larger longitudinal studies will be needed to determine whether these molecular signatures can predict outcomes during life. For now, the message is clear: Parkinson’s disease may share a name and a pathological protein, but the molecular behavior of that protein can be remarkably personal.

Parkinson’s disease, a progressive neurodegenerative disorder characterized by the deterioration of dopaminergic neurons in the substantia nigra, manifests clinically with bradykinesia, rigidity, tremors, and postural instability. Despite advances in symptomatic treatments, notably levodopa and dopamine agonists, these interventions fail to arrest the underlying neurodegeneration, underscoring an urgent need for disease-modifying agents. The c-Abl tyrosine kinase has emerged as a promising molecular target due to its contributory role in alpha-synuclein pathology and mitochondrial dysfunction—hallmarks of Parkinsonian neurodegeneration.

The study, spearheaded by Sarva, H., Pahwa, R., Hernandez-Vara, J., and colleagues, meticulously evaluated vodobatinib’s efficacy and safety profile in a cohort of subjects diagnosed with early Parkinson’s disease. Utilizing a robust clinical protocol, participants were randomized to receive either vodobatinib or placebo over an extended treatment period, with outcomes measured through objective neurological assessments, biomarker analyses, and neuroimaging studies. This design ensured that observed effects could be confidently attributed to the pharmacological intervention, minimizing confounding variables and bias.

Mechanistically, vodobatinib operates by selectively inhibiting the c-Abl tyrosine kinase, an enzyme implicated in aberrant cellular signaling pathways that contribute to neuronal death. The c-Abl kinase is known to phosphorylate parkin, a protein integral to ubiquitin-mediated proteasomal degradation, thereby impairing mitochondrial quality control. Its hyperactivation correlates with accumulation of misfolded alpha-synuclein aggregates and oxidative stress—two pathological features pivotal in Parkinson’s disease progression. By mitigating c-Abl activity, vodobatinib potentially restores cellular homeostasis, prevents neuronal apoptosis, and modulates neuroinflammation.

Results from this phase 2 trial highlight vodobatinib’s capacity not only to slow the clinical decline but also to influence biomarker trajectories associated with disease mechanism. Patients administered with vodobatinib exhibited statistically significant improvements in the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores compared to placebo. These findings extended beyond mere symptomatic relief, suggesting a possible neuroprotective effect. Furthermore, cerebrospinal fluid analyses revealed reduced levels of phosphorylated alpha-synuclein and stabilized mitochondrial function markers, corroborating the drug’s mechanistic intent.

Safety data proved equally encouraging, with vodobatinib demonstrating a tolerable profile consistent across diverse patient demographics. Adverse events were predominantly mild to moderate, including transient gastrointestinal disturbances and fatigue, none resulting in treatment discontinuation. Such findings support the drug’s feasibility for long-term administration, a critical consideration given Parkinson’s chronic trajectory and the necessity for sustained therapeutic intervention.

This trial’s multidimensional evaluation framework included advanced neuroimaging modalities such as positron emission tomography (PET) scans that assessed dopaminergic neuronal integrity and cerebral glucose metabolism. Notably, patients receiving vodobatinib showed attenuation of dopaminergic deficit progression, suggesting preservation of nigrostriatal circuits. This neuroimaging evidence strengthens the hypothesis that c-Abl inhibition can modify the underlying pathology rather than merely palliate symptoms.

The implications of these findings extend into the realm of personalized medicine, offering a foothold for stratifying PD patients who might derive the greatest benefit from c-Abl inhibition based on genetic and molecular profiles. Given the heterogeneity of Parkinson’s disease, understanding how vodobatinib’s efficacy varies with patient-specific variables could guide optimized therapeutic regimens and facilitate more precise prognostication.

Moreover, vodobatinib’s mechanism intersects with broader neurodegenerative disease pathways, raising possibilities for utility beyond Parkinson’s disease. Since c-Abl dysregulation is implicated in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), this therapeutic approach might provide a scaffold for multi-disorder neuroprotective strategies, an exciting frontier warranting further exploration.

Despite the promising outcomes, the authors prudently emphasize the necessity for larger phase 3 trials to confirm vodobatinib’s clinical benefits and delineate its long-term safety profile. Larger sample sizes will enable more granular analyses of clinical endpoints, quality of life measures, and disease progression markers, essential for regulatory approval and subsequent integration into clinical practice.

In the context of existing Parkinson’s therapeutics, this study represents a transformative shift from symptomatic treatment towards targeting disease etiology at a molecular level. The capacity to intervene early in disease progression and potentially alter the neurodegenerative cascade could redefine patient outcomes and healthcare paradigms in movement disorders.

This pioneering research underscores an era where targeted molecular therapies, informed by in-depth understanding of pathogenetic mechanisms, are becoming tangible realities for disorders once deemed intractable. The convergence of medicinal chemistry, biomarker science, and clinical neurology embodied by vodobatinib offers a beacon of hope for millions afflicted by Parkinson’s disease worldwide.

As the field awaits further data, this study stands as a testament to scientific rigor and innovation, illuminating paths to disease modification and affirming the critical importance of translational research in bridging laboratory discoveries with clinical application. For patients, caregivers, and clinicians alike, vodobatinib signals a promising horizon—one where neurodegeneration might be not merely managed but truly challenged at its roots.

Leveraging the layered insights from this trial could catalyze advancements across neurodegenerative research and inspire new investigative models centered on kinase inhibition and mitochondrial fortification. The interdisciplinary collaboration exemplified in this work epitomizes the future of neuromedicine, merging technology and biology to sculpt next-generation therapies.

In conclusion, the clinical evaluation of vodobatinib represents an exceptional stride in Parkinson’s disease research, shining a critical light on c-Abl inhibition as a viable and potent therapeutic pathway. The comprehensive data sets underpin confident optimism for subsequent trials and eventual clinical implementation, potentially transforming the landscape of Parkinson’s treatment and offering renewed hope for a condition historically devoid of disease-modifying options.

Subject of Research: Evaluation of the c-Abl inhibitor vodobatinib in the treatment of early Parkinson’s disease.

Article Title: Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson’s disease: a phase 2, randomized, double-blind, placebo-controlled study.

Article References:
Sarva, H., Pahwa, R., Hernandez-Vara, J. et al. Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson’s disease: a phase 2, randomized, double-blind, placebo-controlled study. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01275-1

Image Credits: AI Generated